Patents Examined by Cecilia Tsang
  • Patent number: 8383594
    Abstract: The present invention relates to the Synthesis of Triterpenoid peptides and mechanism of action for Anti ageing and skin care. The present invention is directed towards anti-aging skin care compositions comprising peptides which are made by linking herbal actives to a pentapeptide for enhanced anti ageing activity by regenerating the dermal matrix. In detail, the present invention relates to the synthesis of Triterpenoid peptides, providing an enhanced and synergistic activity for reducing the consequences of ageing such as appearance of fine expression lines and wrinkles on the skin by cosmetic modes of application. The Triterpenoid peptides of the present invention with its novel dual action mode can be used for skin ageing & collagen insufficiency. Its Triterpenoid group acts by preventing oxidation and excess activity of serine proteases like elastase and collagenase that result in wrinkling of skin.
    Type: Grant
    Filed: August 7, 2007
    Date of Patent: February 26, 2013
    Assignee: Sami Labs Limited
    Inventors: Muhammed Majeed, Renukeshwar H Chandramouli, Kalyanam Nagabhushanam, Rattan Sood, Subbalakshmi Prakash, Susmitha Anand
  • Patent number: 8367053
    Abstract: The present invention provides novel cyclosporin analogue compounds, pharmaceutical compositions comprising these compounds and methods of using these compounds for the treatment of disorders and diseases, including immune disorders, inflammatory disorders and viral infections.
    Type: Grant
    Filed: July 8, 2010
    Date of Patent: February 5, 2013
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Jiang Long, Yat Sun Or, Xuri Gao, Guoqiang Wang
  • Patent number: 8227407
    Abstract: Macrocylic compounds having inhibitory activity on the replication of the hepatitis C virus (HCV) of the general formula (I) X is N, CH and where X bears a double bond it is C; R1a and R1b are hydrogen, C3-7cycloalkyl, aryl, Het, C1-6alkoxy, C1-6alkyl optionally substituted with halo, C1-6alkoxy, cyano, polyhaloC1-6alkoxy, C3-7cycloalkyl, aryl, or with Het; or R1a and R1b together with the nitrogen to which they are attached form a 4 to 6 membered heterocyclic ring which may be optionally substituted; Het being a heterocyclic ring; L is a direct bond, —O—, —O—C1-4alkanediyl-, —O—CO—, —O—C(?O)—NR5a— or —O—C(?O)—NR5a—C1-4alkanediyl-; n is 3, 4, 5, or 6; p is 1, or 2; R2 is hydrogen, and where X is C or CH, R2 may also be C1-6alkyl; R3 is hydrogen, C1-6alkyl, C1-6alkoxyC1-6alkyl, C3-7cycloalkyl, amino, mono- or diC1-6alkylamino; R4 is aryl or a saturated, a partially unsaturated or completely unsaturated 5 or 6 membered monocyclic or 9 to 12 membered bicyclic heterocyclic ring system wherein said ring system
    Type: Grant
    Filed: January 16, 2008
    Date of Patent: July 24, 2012
    Assignees: Medivir AB, Tibotec BVBA
    Inventors: Kenneth Alan Simmen, Herman Augustinus De Kock, Pierre Jean-Marie Bernard Raboisson, Lili Hu, Dominique Louis Nestor Ghislain Surleraux, Karl Magnus Nilsson, Bengt Bertil Samuelsson, Åsa Annica Kristina Rosenquist, Lourdes Salvador Odén
  • Patent number: 8222372
    Abstract: The present invention relates to a method of producing a whey protein hydrolysate using a microbial endopeptidase which specifically cleaves on the carboxy terminal side of arginine or lysine. The invention also relates to use of such whey protein hydrolysate in sports drinks or in clinical nutrition.
    Type: Grant
    Filed: April 15, 2008
    Date of Patent: July 17, 2012
    Assignee: Novozymes A/S
    Inventors: Gitte Budolfsen, Per Munk Nielsen
  • Patent number: 8080519
    Abstract: Pharmaceutical agents, compositions containing the same and methods for their use for enhancing the bioavailability and pharmacological efficacy of therapeutic peptides. The pharmaceutical agents have the formula Carrier-Linker-Peptide Wherein Peptide is a therapeutically active peptide species having the formula aan wherein n is the number of amino acid residues in the peptide and n is 2 to 40, Carrier is benzoyl, phenylacetyl, cinnamoyl, 3-OH-cinnamoyl, 3,4-OH-cinnamoyl, 3,4-dimethoxycinnamoyl, 3,4-methylenedioxycinnamoyl, 3-methoxycinnamoyl, 3,4-diethoxy-cinnamoyl, 3,4,5-trimethoxy-cinnamoyl, t-butoxycarbonyl, benzyloxycarbonyl, pivaloyl, N-9-fluorenylmethoxycarbonyl, fumaroyl and derivatives thereof and Linker is a C6 to C16 lipidic chain or a derivative thereof, an 8-amino-3,6-dioxaoctanoic acid or polymeric derivative thereof, pseudo peptide, or peptide mimic. Methods of use of compositions having the formula Carrier-Peptide wherein Carrier and Peptide are as just defined are also disclosed.
    Type: Grant
    Filed: January 15, 2010
    Date of Patent: December 20, 2011
    Assignee: ImmuPharma SA (France)
    Inventor: Robert H. Zimmer
  • Patent number: 8012481
    Abstract: The present invention relates to the field of neuropathological disorders involving impaired locomotor functions. More specifically, the present invention relates to a composition and method for inducing and restoring locomotor functions, such as basic walking movements in the lower extremities of chronic spinal cord injured animals, such as paraplegic or tetraplegic individuals.
    Type: Grant
    Filed: September 1, 2005
    Date of Patent: September 6, 2011
    Assignee: Universite Laval
    Inventor: Pierre Guertin
  • Patent number: 8008435
    Abstract: A substantially hydrophilic conjugate is provided having a peptide that is capable of passing the blood-brain barrier covalently linked to a water-soluble nonpeptidic polymer such as polyethylene glycol. The conjugate exhibits improved solubility and in vivo stability and is capable of passing the blood-brain barrier of an animal.
    Type: Grant
    Filed: August 25, 2003
    Date of Patent: August 30, 2011
    Assignee: Nektar Therapeutics
    Inventors: Michael David Bentley, Michael James Roberts
  • Patent number: 8008252
    Abstract: The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.
    Type: Grant
    Filed: April 9, 2003
    Date of Patent: August 30, 2011
    Assignee: Novo Nordisk A/S
    Inventors: Shawn DeFrees, David Zopf, Robert Bayer, Caryn Bowe, David Hakes, Xi Chen
  • Patent number: 8008093
    Abstract: A method of treating a blistering disorder, which includes administering to a target tissue in a subject in need thereof an effective amount of a composition that inhibits activation of the HSP27 phosphorylation pathway.
    Type: Grant
    Filed: December 2, 2005
    Date of Patent: August 30, 2011
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: David Scott Rubenstein, Paula Berkowitz, Peiqi Hu, Luis Alberto Diaz
  • Patent number: 8008262
    Abstract: ?-peptide regions of polypeptides can serve as structural mimics of ?-helices in wild type proteins. Because ?-helices of one protein often bind to a target protein in a biological pathway, a polypeptide that contains a helical ?-peptide region can be used to disrupt this type of protein-protein binding. As a result, polypeptides that contain a helical ?-peptide region can be used to treat conditions involving this type of protein-protein binding, such as viral infections and cell proliferation.
    Type: Grant
    Filed: April 21, 2005
    Date of Patent: August 30, 2011
    Assignee: Yale University
    Inventors: Alanna Schepartz Shrader, Scott A. Hart, Joshua A. Kritzer, Olen M. Stephens
  • Patent number: 8003608
    Abstract: The present invention relates to the use of a compound of the formula Lys-X where X is a hydroxyl group, an amino group, alkoxy, Pro or Pro-Thr, or of a pharmaceutically acceptable salt thereof, for the treatment of inflammations. The invention also relates to the use of ?MSH for inducing tolerance.
    Type: Grant
    Filed: February 8, 2002
    Date of Patent: August 23, 2011
    Inventor: Thomas Luger
  • Patent number: 8003604
    Abstract: Macrocyclic peptides having the general formula: are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
    Type: Grant
    Filed: November 14, 2007
    Date of Patent: August 23, 2011
    Assignee: Bristol-Myers Squibb Company
    Inventors: Alan Xiangdong Wang, Barbara Zhizhen Zheng, Stanley D'Andrea, Nicholas A. Meanwell, Paul Michael Scola
  • Patent number: 7998960
    Abstract: For the separation, removal, isolation, purification, characterization, identification or quantification of plasminogen or a protein that is a plasminogen analogue, an affinity adsorbent is used that is a compound of formula (II) wherein one X is N and the other is N, C—Cl or C—CN; A is a support matrix, optionally linked to the triazine ring by a spacer; Z is O, S or N—R and R is H, C1-6 alkyl, C1-6 hydroxyalkyl, benzyl or &bgr;-phenylethyl; B is an optionally substituted hydrocarbon linkage containing from 1 to 10 carbon atoms; D is H, OH or a primary amino, secondary amino, tertiary amino, quaternary ammonium, imidazole, guanidino or amidino group; or B-D is —CHCOOH—(CH2)3-4—NH2; and q is 2 to 6.
    Type: Grant
    Filed: May 9, 2006
    Date of Patent: August 16, 2011
    Assignee: Prometic Biosciences Ltd.
    Inventors: Jason Richard Betley, James Christopher Pearson, Claudia Hildegard Kuhn, Baldev Singh Baines
  • Patent number: 7994122
    Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain in a subject. In particular, the invention provides novel glucagon analogue peptides effective in such methods and in the treatment of obesity, eating disorders, metabolic syndrome, and non-alcoholic liver steatosis. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Grant
    Filed: June 16, 2008
    Date of Patent: August 9, 2011
    Assignee: Zealand Pharma A/S
    Inventors: Ditte Riber, Eddi Meier, Trine Skovlund Ryge, Jens Rosengren Daugaard
  • Patent number: 7964560
    Abstract: Hepatitis C virus inhibitors having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
    Type: Grant
    Filed: May 27, 2009
    Date of Patent: June 21, 2011
    Assignee: Bristol-Myers Squibb Company
    Inventors: Alan Xiangdong Wang, Paul Michael Scola
  • Patent number: 7964702
    Abstract: The invention provides a cyclomonomer having actin-binding activity. The cyclomonomer is of utility for the study of the molecular biology of actin polymerization. The cyclomonomer is also useful for the study of and treatment of the toxic effects of Amanita sp. poisoning.
    Type: Grant
    Filed: May 4, 2007
    Date of Patent: June 21, 2011
    Assignee: The Regents of the University of California
    Inventors: R. Scott Lokey, Laura A. Schuresko
  • Patent number: 7960342
    Abstract: SRIF peptide antagonists, which are selective for SSTR2 in contrast to the other cloned SRIF receptors and which bind with high affinity to the cloned human receptor SSTR2 but do not activate the receptor, have many useful functions. Because they do not bind with significant affinity to SSTR1, SSTR3, SSTR4 or SSTR5, their administration avoids potential undesirable side effects. Because they block the receptor function, they can be used therapeutically to block certain physiological effects which SSTR2 mediates. By incorporating radioiodine or the like in these SSTR2-selective SRIF antagonists, a labeled compound useful in drug-screening methods is provided. Alternatively, for use in therapy, highly radioactive moieties can be N-terminally coupled, complexed or chelated thereto.
    Type: Grant
    Filed: October 15, 2007
    Date of Patent: June 14, 2011
    Assignees: The Salk Institute for Biological Studies, Universitat Bern, University Hospital Basel
    Inventors: Jean E. F. Rivier, Judit Erchegyi, Jean Claude Reubi, Helmut R. Maecke
  • Patent number: 7956032
    Abstract: The present invention provides conjugates between Granulocyte Colony Stimulating Factor and PEG moieties. The conjugates are linked via an intact glycosyl linking group that is interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from both glycosylated and unglycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto either an amino acid or glycosyl residue on the peptide. Also provided are pharmaceutical formulations including the conjugates. Methods for preparing the conjugates are also within the scope of the invention.
    Type: Grant
    Filed: June 23, 2005
    Date of Patent: June 7, 2011
    Assignee: Novo Nordisk A/S
    Inventors: Shawn DeFrees, David A. Zopf, Zhi-Guang Wang, Caryn Bowe
  • Patent number: 7956158
    Abstract: A polypeptide comprising a first protein domain, a second protein domain, and a dithiocyclopeptide spacer containing at least one protease cleavage site, wherein the dithiocyclopeptide is exogenous relative to the first or second protein domain, and wherein the first and second protein domains are operably linked by the dithiocyclopeptide. Also disclosed are methods of producing the polypeptide and delivering the protein domains into a cell.
    Type: Grant
    Filed: March 28, 2008
    Date of Patent: June 7, 2011
    Assignee: University of Southern California
    Inventor: Wei-Chiang Shen
  • Patent number: RE43371
    Abstract: This invention relates to the use in the treatment of HCV infection, either as single active agents or in combination with another active agent, of a cyclosporin having increased cyclophilin binding activity and essentially lacking immunosuppressive activity.
    Type: Grant
    Filed: October 29, 2010
    Date of Patent: May 8, 2012
    Inventors: Pietro Scalfaro, Jean-Maurice Dumont, Gregoire Vuagniaux, Rolland-Yves Mauvernay